Jasmine sambac L. essential oil attenuates inflammation and pain via TRPV1
- 24.09.2025
- Original Article
- Verfasst von
- Sahar Jaffal
- Aluck Thipayarat
- Samer Alqaraleh
- Jakrapop Wongwiwat
- Pattarin Supanivatin
- Erschienen in
- Inflammopharmacology | Ausgabe 10/2025
Abstract
Pain and inflammation are complex physiological responses. The drugs that are available in the market have multiple side effects. Thus, the search for safer effective therapeutics became a significant area of research. In this study, Jasmine sambac L. essential oil, which is aromatic and therapeutic in nature, has been studied for its potential anti-inflammatory and anti-nociceptive activities as well as its mechanism of action. The findings from this research indicated that the intraplantar (ipl) administration of jasmine essential oil to the animals produced anti-inflammatory effects in the carrageenan-induced paw edema model. In addition, jasmine essential oil showed significant inhibition of pain responses compared to the control group in the acetic acid-induced writhing test and immersion tail-flick test. These findings suggest that jasmine oil exhibits anti-nociceptive and anti-inflammatory effects in animals. More data are needed to determine its therapeutic value in human clinical trials. The anti-inflammatory and anti-nociceptive effects were mediated by the transient receptor potential vanilloid 1 (TRPV1), a key pain receptor. The chemical composition of jasmine essential oil was analyzed by gas chromatography-mass spectrometry (GC–MS) to determine the bioactive constituents that can be responsible for these effects. The results showed that the oil consists of active constituents with various therapeutic activities as reported in earlier studies. Thus, jasmine essential oil can be utilized as a complementary therapy for pain and inflammation treatment.
Anzeige
- Titel
- Jasmine sambac L. essential oil attenuates inflammation and pain via TRPV1
- Verfasst von
-
Sahar Jaffal
Aluck Thipayarat
Samer Alqaraleh
Jakrapop Wongwiwat
Pattarin Supanivatin
- Publikationsdatum
- 24.09.2025
- Verlag
- Springer International Publishing
- Erschienen in
-
Inflammopharmacology / Ausgabe 10/2025
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608 - DOI
- https://doi.org/10.1007/s10787-025-01929-1
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.